Milestone first patent for Proteomics simple endometriosis test
In a milestone moment, ASX-listed diagnostics innovator Proteomics International Laboratories has achieved its first patent globally in Japan for its simple 'traffic light' diagnostic blood test for endometriosis.
The decision will protect the company's intellectual property rights for its PromarkerEndo technology in the world's fourth-largest healthcare market until March 16, 2041.
Proteomics says Japan's healthcare sector already widely uses in vitro diagnostics and precision medicine technologies to customise treatments for patients and help deliver better patient outcomes.
The company is planning to start an international commercial roll-out of the device within months using its existing direct-to-consumer channels, while also tapping into general practitioners and women's health specialists.
'This is a significant achievement because it validates the novelty of PromarkerEndo, our world-first blood test for endometriosis.'
Proteomics International managing director Dr Richard Lipscombe
Proteomics International managing director Dr Richard Lipscombe said: 'Securing patent protection for our diagnostic technology in this region is a key step in our global commercialisation pathway and provides a strong foundation for potential partnerships, licensing, and regulatory advancement.'
PromarkerEndo promises to revolutionise women's reproductive healthcare by delivering the first clinically viable, real-world, non-invasive diagnostic test for a disease affecting one in nine women and girls. Estimates suggest endometriosis costs the Australian economy nearly $10 billion annually.
Its symptoms can be devastating for women, but it has historically been difficult to diagnose. It can take up to seven years on average for women to be diagnosed with endometriosis, using painful and invasive laparoscopy and tissue biopsies, performed under anaesthetics.
For the first time, doctors may instead be able to turn to PromarkerEndo as a frontline tool in detecting endometriosis in symptomatic patients. The device uses a universal 'traffic light' risk score - low, moderate or high - to indicate a patient's likelihood of having the disease.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Herald Sun
4 hours ago
- Herald Sun
Non-binary Australian suicide contemplation rates soar, Kat Elsby shares experience
Don't miss out on the headlines from Mental Health. Followed categories will be added to My News. Growing up, Kat Elsby always felt like there was something missing. Assigned female at birth, Kat felt like an 'alien dropped off on the wrong planet' most of their life. 'I felt like an alien that just looked like everyone else but didn't feel like them,' Kat, who is a non-binary trans person, said. 'I just didn't understand people talking about feeling like a girl or a woman. 'None of this stuff made sense to me.' This feeling took a heavy toll on Kat's mental health, including suicidal thoughts and attempts. It wasn't until Kat was 23 that they learnt about gender diverse terms and everything clicked. 'It was like a light bulb going off in my head and a huge part of myself suddenly made sense,' Kat, now 38, said. 'I've known these things about myself my whole life, I just didn't have the words to describe them. 'But it was also that knowledge of if there's other people out there like me, I'll be able to find them.' Despite growing awareness of mental health issues, suicide remains a critical concern for the nation's LGBTQ+ community. Non-binary people are among the most vulnerable, experiencing mental health issues at more than double the rate of cisgender people. According to the Australian Institute of Health and Welfare, 79 per cent of non-binary people have experienced suicidal thoughts compared to 14 per cent of men and 18 per cent of women. 'It's the norm to think maybe the world would be better off if I wasn't here and that is absolutely heartbreaking,' Kat said. 'We lose so many people because it's not just that people struggle with these thoughts, it's that they act on them.' The Adelaide local, who trains suicide prevention workers at prevention organisation Roses in the Ocean, said peer support from LGBTQ+ people with lived experience went a long way. Through the organisation's Peer CARE Companion Warmline, people can connect with someone 'who shares aspects of their identity'. 'It makes a real difference when people can connect with someone who's walked a similar path.' Proper training in LGBTQ+ services and correct pronoun use is crucial for inclusive healthcare. 'Some services still don't get the basics right,' Kat said. 'People often have to educate services about their gender identity or sexuality just to get support.' For those struggling with their mental health, it's never too late to reach out. 'There are people out there that will understand you and they will accept you,' Kat said. 'It can feel very lonely but there are fantastic spaces out there like Shine SA, Thorne Harbour Health, Headspace and Safe Haven.' If you or a loved one needs support, call Lifeline on 13 11 41 Originally published as Kat Elsby uses lived experience to train non-binary suicide prevention workers as Australian contemplation rates soar
News.com.au
5 hours ago
- News.com.au
Closing Bell: Healthcare sector gives ASX a booster to rise 0.33pc
ASX lifts 0.33pc on healthcare sector strength CSL adds 2.4pc as UBS marks ASX healthcare sector as best EPS pick Chinese manufacturing data contracts, but shows signs of stirring Are healthcare bulls returning? The ASX healthcare sector was the best performing of the ASX's 11 subcategories in trade today, handily outperforming the other sectors with a 1.58% jump. With support from industrials (+1%) and consumer discretionary (+0.98%), that was enough for the ASX 200 to make a convincing gain of 0.33% today, having had a steady run of momentum throughout trade. Regis Healthcare (ASX:REG) added 3.2%, Ramsay Health Care (ASX:RHC) 1.9% and Summerset Group (ASX:SNZ) 1.3%. As for our healthcare giants, CSL (ASX:CSL) gained 2.4%, Pro Medicus (ASX:PME) 2% and Cochlear (ASX:COH) 1.7%. If financial giant UBS is to be believed, this may be the start of a bit of a bullish run for ASX biotech stocks, which have been suffering over the past few months. UBS reckons the ASX healthcare sector is now undervalued, offering the best earnings-per-share growth of all sectors, and forecasting a 20% increase in the 2025-26 year. 'Investor sentiment towards the healthcare sector has broadly cooled over the past year, with some marked deterioration seen across many stocks,' UBS says. 'Cochlear in particular has seen investor apathy build over the last year, which represents a significant change of views.' Back on the ASX today, the main drag was in the materials sector, down 0.77%. The ASX 200 Resources index was also an anchor, shedding 0.96%, but it was outweighed by gains in the All Tech, Gold and Small Ords indices. Chinese manufacturing data contracts again While iron ore has been enjoying a small uptick in pricing the past five days or so, the latest data out of China isn't the best news for Aussie base metal stocks. Manufacturing activity from our largest trading partner fell again for a third month straight in June, despite Beijing's attempts to stimulate the sector. The official purchasing manager's index did improve slightly from 49.5 in May to 49.7 in June, but remained below the 50-point benchmark which indicates whether the index is expanding or contracting. Inventory and employment levels at factories fell as well, but the news wasn't all bad. The sub-index tracking manufacturing production rose to 51 and new orders lifted to 50.2, which could indicate the first stirrings of momentum beginning to build in China's industrial activity. Chinese Premier Li Qiang said Chinese authorities would implement measures to 'make China a mega-sized consumption powerhouse' as well as a manufacturing one in a speech at the World Economic Forum's annual conference in China. 'We still think that there are challenges this year, but I think it's not as far-fetched as we thought before,' Oxford Economics lead economist for China Louise Loo said. 'However punitive tariffs are, I think in the near term, it's quite hard to decouple China from global supply chains, and that means we will continue to see China exports, at least, remain quite competitive, and that should support economic growth for the Chinese.' It remains to be seen if that will translate into higher demand for Australian iron ore, but one can hope. ASX SMALL CAP LEADERS Today's best performing small cap stocks: Security Name Last % Change Volume Market Cap WEL Winchester Energy 0.002 100% 165600 $1,363,019 LSR Lodestar Minerals 0.011 83% 42455380 $1,910,543 ADD Adavale Resource Ltd 0.0015 50% 15489651 $2,287,279 ADY Admiralty Resources. 0.006 50% 1690337 $10,517,918 EEL Enrg Elements Ltd 0.0015 50% 860601 $3,253,779 MPR Mpower Group Limited 0.01 43% 5225088 $2,405,923 GTE Great Western Exp. 0.011 38% 3625782 $4,542,063 MEG Megado Minerals Ltd 0.023 35% 4786016 $10,313,615 ALM Alma Metals Ltd 0.004 33% 2325000 $5,261,182 FCT Firstwave Cloud Tech 0.016 33% 3070713 $20,562,224 FHS Freehill Mining Ltd. 0.004 33% 15028446 $10,241,561 GTR Gti Energy Ltd 0.004 33% 5538733 $8,996,849 SPX Spenda Limited 0.008 33% 16838995 $27,691,293 GLH Global Health Ltd 0.068 33% 176778 $2,987,301 AAU Antilles Gold Ltd 0.005 25% 6046776 $9,516,272 ERL Empire Resources 0.005 25% 692641 $5,935,653 RCM Rapid Critical 0.0025 25% 1125000 $2,831,556 ROG Red Sky Energy. 0.005 25% 120000 $21,688,909 TMX Terrain Minerals 0.0025 25% 5339766 $5,063,629 VR1 Vection Technologies 0.036 24% 40421798 $51,255,235 THR Thor Energy PLC 0.011 22% 2677843 $6,397,109 KNB Koonenberrygold 0.039 22% 46537381 $32,790,159 RPG Raptis Group Limited 0.063 21% 185561 $18,235,612 NGX Ngxlimited 0.145 21% 45773 $10,873,421 SDV Scidev Ltd 0.36 20% 293999 $57,026,459 Making news… Lodestar Minerals (ASX:LSR) is looking to follow up on gold hits at its Chilean copper-gold projects with proceeds from a $2.2m two-tranche share placement. LSR is offering $475k in the first tranche to clients of lead manager Oakley Capital Partners, with the rest hanging on shareholder approval. Adavale Resources (ASX:ADD) is preparing to put drill bit to ground at the London Victoria Mine in NSW, which historically produced gold grades up to 43.8 g/t gold. It's the first exploration at the mine in 30 years; ADD will target shallow extensions to the existing mineral resource estimate, which currently sits at 115,000 ounces of gold. FirstWave Cloud Technology (ASX:FCT) has inked a licensing agreement with Claro Dominican Republic to license its NMIS v9 network management software suite for an upfront fee of US$250k. It's a pure-profit contract, as the contract doesn't require delivery, support or professional services. GTI Energy (ASX:GTR) is locking in a $4.5m placement at an issue price of 0.035 cents a share, a 16.7% premium to the last close price of 0.030 cents. The money will be funnelled directly to resource expansion and infill drilling at the Lo Herma uranium project. GTR's recent scoping study revealed a potential pre-tax net present value of between $174m and $187m and an internal rate of return of between 52% and 66% for Lo Herma. Check out Stockhead's Break it Down for more on GTR's capital raising. Spenda (ASX:SPX) has teamed up with APG Pay Pty Ltd to develop and commercialise a corporate credit platform. The two companies will collab on a scaleable B2B payments space that can scale across multiple industries, starting with the travel industry. Spenda reckons the deal will bring in recurring profit of $1.7m per year. ASX SMALL CAP LAGGARDS Today's worst performing small cap stocks: Security Name Last % Change Volume Market Cap CT1 Constellation Tech 0.001 -50% 1322698 $2,949,467 IS3 I Synergy Group Ltd 0.002 -50% 3892995 $2,002,920 T3D 333D Limited 0.006 -33% 33333 $1,585,651 ADR Adherium Ltd 0.004 -33% 3436600 $5,390,874 TEG Triangle Energy Ltd 0.002 -33% 4164703 $6,267,702 TKL Traka Resources 0.001 -33% 135263 $3,188,685 L1M Lightning Minerals 0.043 -28% 1471249 $6,199,699 ZMM Zimi Ltd 0.008 -27% 616731 $4,702,982 FIN FIN Resources Ltd 0.003 -25% 557800 $2,779,554 GMN Gold Mountain Ltd 0.0015 -25% 1983598 $11,239,518 HLX Helix Resources 0.0015 -25% 1234287 $6,728,387 SFG Seafarms Group Ltd 0.0015 -25% 893383 $9,673,198 SRN Surefire Rescs NL 0.0015 -25% 334051 $4,972,891 TYX Tyranna Res Ltd 0.003 -25% 325000 $13,153,701 GLA Gladiator Resources 0.007 -22% 1626499 $6,824,671 YAR Yari Minerals Ltd 0.012 -20% 2978290 $8,320,672 AUK Aumake Limited 0.002 -20% 1177734 $7,558,397 MEM Memphasys Ltd 0.004 -20% 6329063 $9,917,991 MKL Mighty Kingdom Ltd 0.016 -20% 1737419 $10,326,928 PPG Pro-Pac Packaging 0.016 -20% 78233 $3,633,754 RAN Range International 0.002 -20% 2187661 $2,348,226 SKK Stakk Limited 0.004 -20% 2620995 $10,375,398 VEN Vintage Energy 0.004 -20% 1780465 $10,434,568 HIQ Hitiq Limited 0.014 -18% 1054211 $7,814,865 BDM Burgundy D Mines Ltd 0.029 -17% 604995 $49,746,630 IN CASE YOU MISSED IT QPM Energy (ASX:QPM) is powering up with plans for a new gas-fired plant at the Isaac Energy Hub. Astute Metals (ASX:ASE) has identified four high-priority gold-silver targets at its Needles project in Nevada, USA, thanks to a data review. Green Critical Minerals (ASX:GCM) has cleared another hurdle at the McIntosh graphite project with a PFS showcasing robust economics including $25m post-tax NPV, 25.3% IRR and a 32.5-year mine life. LTR Pharma (ASX:LTP) has completed extractables studies for its Spontan intranasal spray for erectile dysfunction and kicked off a leachables study. Ausgold (ASX:AUC) has released a positive definitive feasibility study for its Katanning gold project (KGP) in WA, highlighting robust returns over a 10-year mine life. Theta Gold Mines' (ASX:TGM) board has rubber stamped the TGME mine in South Africa's Mpumalanga region as high gold prices stir investment in the historic mining district. Break it Down: Anson Resources (ASX:ASN) has paired up with a Korean battery maker to develop a DLE demonstration plant at the Green River project in Utah. Redcastle Resources (ASX:RC1) is on its way to becoming an integrated exploration and production company after lifting resources to 42,000oz at the Redcastle project. TRADING HALTS Australian Mines (ASX:AUZ) – cap raise and potential acquisition AuKing Mining (ASX:AKN) – cap raise Battery Age Minerals (ASX:BM8) – cap raise Blackstone Minerals (ASX:BSX) – cap raise archTIS (ASX:AR9) – cap raise Lodestar Minerals (ASX:LSR) – cap raise Liontown Resources (ASX:LTR) – executive changes Olympio Metals (ASX:OLY) – cap raise Peak Minerals (ASX:PUA) – response to ASX price query Red Mountain Mining (ASX:RMX) – cap raise (ASX:RNT) – cap raise Terra Uranium (ASX:T92) – acquisition and cap raise Vitasora Health (ASX:VHL) – cap raise At Stockhead, we tell it like it is. While GTI Energy is a Stockhead advertiser, it did not sponsor this article.
The Age
6 hours ago
- The Age
Milestone first patent for Proteomics simple endometriosis test
In a milestone moment, ASX-listed diagnostics innovator Proteomics International Laboratories has achieved its first patent globally in Japan for its simple 'traffic light' diagnostic blood test for endometriosis. The decision will protect the company's intellectual property rights for its PromarkerEndo technology in the world's fourth-largest healthcare market until March 16, 2041. Proteomics says Japan's healthcare sector already widely uses in vitro diagnostics and precision medicine technologies to customise treatments for patients and help deliver better patient outcomes. The company is planning to start an international commercial roll-out of the device within months using its existing direct-to-consumer channels, while also tapping into general practitioners and women's health specialists. 'This is a significant achievement because it validates the novelty of PromarkerEndo, our world-first blood test for endometriosis.' Proteomics International managing director Dr Richard Lipscombe Proteomics International managing director Dr Richard Lipscombe said: 'Securing patent protection for our diagnostic technology in this region is a key step in our global commercialisation pathway and provides a strong foundation for potential partnerships, licensing, and regulatory advancement.' PromarkerEndo promises to revolutionise women's reproductive healthcare by delivering the first clinically viable, real-world, non-invasive diagnostic test for a disease affecting one in nine women and girls. Estimates suggest endometriosis costs the Australian economy nearly $10 billion annually. Its symptoms can be devastating for women, but it has historically been difficult to diagnose. It can take up to seven years on average for women to be diagnosed with endometriosis, using painful and invasive laparoscopy and tissue biopsies, performed under anaesthetics. For the first time, doctors may instead be able to turn to PromarkerEndo as a frontline tool in detecting endometriosis in symptomatic patients. The device uses a universal 'traffic light' risk score - low, moderate or high - to indicate a patient's likelihood of having the disease.
